Washington University in Saint Louis
Welcome,         Profile    Billing    Logout  
 73 Trials 
152 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Connolly, Anne
NCT05412394: Once Weekly Infant Corticosteroid Trial for DMD

Recruiting
4
26
US
Prednisolone, Corticosteroid
Anne M. Connolly, Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Medical Center, Cincinnati, Muscular Dystrophy Association, University of Texas, Virginia Commonwealth University
Duchenne Muscular Dystrophy
08/26
12/26
EMERGENE, NCT06246513: A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Recruiting
3
15
Europe, US
SRP-9003, scAAVrh74.MHCK7.hSGCB, bidridistrogene xeboparvovec, Glucocorticoid, Prednisone or equivalent
Sarepta Therapeutics, Inc.
Limb-girdle Muscular Dystrophy
01/25
11/29
NCT06503367: Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy

Not yet recruiting
N/A
44
US
Nationwide Children's Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Medical Center, Cincinnati, University of Iowa, Washington University School of Medicine, Stanford University, University of Utah, University of Rochester, University of Pittsburgh, University of Texas, Southwestern Medical Center at Dallas, University of Minnesota, UCLA Ronald Reagan Medical Center, Boston Children's Hospital
LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)
09/28
09/28
Ewald, Gregory A
REBIRTH, NCT05180773: Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Recruiting
4
250
US
Bromocriptine, Parlodel, Cycloset, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Xarelto, Second Placebo
Dennis M. McNamara, MD, MS, National Heart, Lung, and Blood Institute (NHLBI)
Peripartum Cardiomyopathy, Postpartum
06/26
12/28
SmartHF, NCT05858320: The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients

Recruiting
3
225
US
SmartHF application
University of Michigan, Washington University, Barns Jewish Hospital, St. Louis, MO, Henry Ford Hospital, Detroit, MI, Emory University, Grady Hospital, Atlanta, GA
Heart Failure
06/26
06/26
MUSIC-HFrEF1, NCT04703842: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Recruiting
1/2
57
US
SRD-001, Placebo
Sardocor Corp., Covance
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
12/25
12/28
NCT04840914: A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Completed
1
44
Japan, US
LY3461767, Placebo
Eli Lilly and Company
Chronic Heart Failure With Reduced Ejection Fraction
05/24
05/24
Tine, Brian Van
NCT06422806: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Recruiting
3
180
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475
National Cancer Institute (NCI)
Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Undifferentiated Pleomorphic Sarcoma
06/26
06/26
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery

Recruiting
2
26
US
Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma
12/18
12/18
NCI protocol 10250, NCT03880019: A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Active, not recruiting
2
23
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Core Biopsy, BIOPSY, CORE, CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma
08/20
09/25
SPEARHEAD-1, NCT04044768 / 2019-000589-39: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Active, not recruiting
2
52
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune, Adaptimmune LLC
Synovial Sarcoma, Myxoid Liposarcoma
08/21
04/38
NCT02584309: Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Completed
2
73
US
Dexrazoxane, Zinecard®, Totect®, Doxorubicin, Adriamycin, Hydroxydaunomycin Hydrochloride, Hydroxydoxorubicin Hydrochloride, Rubex
Washington University School of Medicine
Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
07/22
07/22
NCT04200443: Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Active, not recruiting
2
72
US
Cabozantinib, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Unresectable Soft Tissue Sarcoma
04/25
04/25
SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated
2
3
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells
Adaptimmune, ICON plc
Esophageal Cancer, Esophagogastric Junction Cancer
06/23
12/23
NCT04595747: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting
2
48
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rogaratinib, BAY-1163877, BAY1163877
National Cancer Institute (NCI)
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
01/25
01/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT04551430: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting
2
105
US
Cabozantinib, Nivolumab, Opdivo, Ipilimumab, Yervoy
Washington University School of Medicine, Exelixis, Bristol-Myers Squibb
Metastatic Soft-tissue Sarcoma
06/24
06/30
NCT04040205: Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Recruiting
2
44
US
Abemaciclib, Verzenio
Medical College of Wisconsin
Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
06/25
06/26
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
ZIABC011078, NCT03141684: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Hourglass Oct 2024 - Dec 2024 : Regulatory approval for alveolar soft part sarcoma
Active, not recruiting
2
63
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
10/25
10/25
NCT05440786 / 2021-004734-11: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Sarcoma, Ewing, Neoplasm Metastasis
02/27
09/28
NCT02584647: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Active, not recruiting
1/2
43
US
PLX3397, No other name, Sirolimus, Rapamune
Gulam Manji, Daiichi Sankyo
Sarcoma, Malignant Peripheral Nerve Sheath Tumors
07/23
06/24
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
NCT04892017: A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Recruiting
1/2
144
US
DCC-3116, Trametinib, Binimetinib, Sotorasib
Deciphera Pharmaceuticals, LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
08/27
08/28
NCT04887298: Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

Completed
1/2
36
US
Liposomal Annamycin (L-Annamycin)
Moleculin Biotech, Inc.
Sarcoma,Soft Tissue, Pulmonary Metastasis
09/22
08/24
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
NCT05588648: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Recruiting
1/2
48
US, RoW
Vactosertib, TEW-7197
MedPacto, Inc.
Osteosarcoma
07/25
11/25
NCT05813327: Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Recruiting
1/2
35
US
ADI PEG20, PEGylated arginine deiminase, Ifosfamide, ifex, Radiotherapy, Mesna, sodium 2-mercaptoethane sulfonate
Washington University School of Medicine, Polaris Group
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
01/26
01/28
NCT03921008: Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

Recruiting
1/2
19
US
Paclitaxel, Taxol, Radiation therapy, Research blood draw
Washington University School of Medicine
Cutaneous Angiosarcoma
08/28
08/28
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
NCT05616624: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Recruiting
1/2
114
US
ADI-PEG 20, PEGylated arginine deiminase, Gemcitabine, Gemzar, Docetaxel, Taxotere
Washington University School of Medicine, Polaris Group
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
12/27
12/32
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
SURPASS, NCT04044859: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Checkmark Results from SURPASS trial for MAGE-4 positive tumors
Sep 2022 - Sep 2022: Results from SURPASS trial for MAGE-4 positive tumors
Checkmark Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Nov 2019 - Nov 2019: Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Recruiting
1
120
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Adaptimmune, ICON plc
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
12/25
04/37
NCT03761095: A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Completed
1
41
US
Unesbulin, PTC596, Dacarbazine, DTIC
PTC Therapeutics
Leiomyosarcoma
02/24
02/24
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1
49
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
INDP-D101, NCT05651022: DECOY20 Study in Patients with Advanced Solid Tumors

Recruiting
1
120
US
Decoy20
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult
06/27
09/27
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Recruiting
N/A
100
US
Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
12/25
12/25
NCT03141021: Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Recruiting
N/A
1050
Europe, Canada, Japan, US, RoW
Washington University School of Medicine, Boston's Children Hospital
Malignant Peripheral Nerve Sheath Tumors
04/53
04/53
Bateman, Randall
DIAN-TU, NCT06384573: Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Recruiting
3
65
Europe, US, RoW
lecanemab, BAN2401
Washington University School of Medicine, Alzheimer's Association, Eisai Inc.
Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
11/29
11/29
DIAN-TU, NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Terminated
2/3
73
Europe, US, RoW
Gantenerumab, RO4909832
Washington University School of Medicine, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
10/23
11/23
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
NCT03938870: CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease

Completed
N/A
96
US
L-Leucine 13C6
Washington University School of Medicine, BrightFocus Foundation, National Institutes of Health (NIH)
Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders, Dementia, Mental Disorders, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies
07/23
07/23
SEABIRD, NCT03899844: Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

Completed
N/A
1122
US
Blood collection, PiB PET/MRI, and cognitive testing
Washington University School of Medicine
Alzheimer Disease, Alzheimer Dementia
01/24
01/24
DIAN, NCT00869817: Dominantly Inherited Alzheimer Network

Recruiting
N/A
700
Europe, Canada, Japan, US, RoW
Washington University School of Medicine, National Institute on Aging (NIA)
Alzheimer's Disease
07/25
07/25
SUNBIRD, NCT06547099: Study to Understand Novel Biomarkers in Researching Dementia

Enrolling by invitation
N/A
1800
US
Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
Washington University School of Medicine, National Institute on Aging (NIA)
Alzheimer Disease, Mild Cognitive Impairment, Dementia
12/28
12/28
Conway, Charles R
NCT03736538: Nitrous Oxide- Suicidal Ideation

Enrolling by invitation
1
50
US
Nitrous Oxide, Laughing Gas, Placebo gas
Washington University School of Medicine, American Foundation for Suicide Prevention
Major Depressive Disorder, Depression, Mood Disorders, Suicidal Ideation
06/24
07/24
NCT02942368: Adaptive tDCS for Treatment-Resistant MDD

Active, not recruiting
N/A
25
US
tDCS
Washington University School of Medicine
Depressive Disorder, Treatment-Resistant
06/24
06/24
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Haroutounian, Simon
CARES, NCT05722002: Comparing Analgesic Regimen Effectiveness and Safety for Surgery () Trial

Recruiting
4
900
Canada, US
NSAID, Opioid, Acetaminophen
University of Michigan, Patient-Centered Outcomes Research Institute
Surgery, Pain, Postoperative
04/25
10/25
KALPAS, NCT05037123: Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

Recruiting
3
750
US
Continuous ketamine infusion, Ketamine + Saline, Placebo
NYU Langone Health, National Cancer Institute (NCI)
Chronic Postsurgical Pain
10/24
10/25
NCT04603066: Tariquidar-ondansetron Combination in Neuropathic Pain

Completed
1/2
23
US
Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo
Washington University School of Medicine
Neuropathic Pain
10/23
11/23
EPIPHANY, NCT03997981: Chemotherapy Induced Peripheral Neuropathy Natural History Study

Recruiting
N/A
200
US
Disarm Therapeutics, Eli Lilly and Company
Chemotherapy-induced Peripheral Neuropathy
03/24
04/24
NCT05575128: Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures

Recruiting
N/A
100
US
Behavioral activation, Medication optimzation, Care as usual
Washington University School of Medicine, National Institute of Mental Health (NIMH)
Cardiac Surgery, Older Adults, Depression, Anxiety
11/24
03/25
NCT05685511: Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery

Recruiting
N/A
110
US
Behavioral Activation, Medication Optimization
Washington University School of Medicine, National Institute of Mental Health (NIMH)
Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
05/25
05/25
CPMH, NCT05697835: Perioperative Mental Health in Orthopedic Surgery

Recruiting
N/A
100
US
Behavioral activation, Medication optimzation, Care as usual
Washington University School of Medicine, National Institute of Mental Health (NIMH)
Orthopedic Surgery, Older Adults, Depression, Anxiety
02/26
02/26
P5, NCT04864275: Personalized Prediction of Persistent Postsurgical Pain

Recruiting
N/A
2750
US
Washington University School of Medicine
Pain, Postoperative
04/26
10/26
Lasala, John
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Mueller, Sabine
NCT01734512: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Completed
2
65
US
Everolimus
University of California, San Francisco, Novartis Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium, The Pediatric Low Grade Astrocytoma (PLGA) Foundation
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
01/20
07/24
NCT05123534: A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

Suspended
2
15
US
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS), Exablate Type 2.0
SonALAsense, Inc.
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
07/24
10/24
NCT05009992: Combination Therapy for the Treatment of Diffuse Midline Gliomas

Hourglass Jun 2024 - Jul 2024 : Follow up data for DMG
Recruiting
2
360
Europe, US, RoW
ONC201, TIC10, Antagonist of dopamine receptor D2 (DRD2) and caseinolytic protease proteolytic subunit (ClpP), Radiation Therapy, Radiotherapy, Paxalisib, Inhibitor of the PI3K/AKT/mTOR pathway, GDC-0084, GDC0084, PI3K Inhibitor GDC-0084
University of California, San Francisco, The Chad-Tough Defeat DIPG Foundation, Mithil Prasad Foundation, Storm the Heavens Fund, National Institute of Neurological Disorders and Stroke (NINDS)
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
12/25
06/29
PNOC029, NCT05465174: Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
56
US
Nivolumab, Opdivo, Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Bristol-Myers Squibb, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
NCT03690869 / 2023-000604-19: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Calendar Jan 2025 - Dec 2025: From trial n pediatrics with solid tumors
Terminated
1/2
57
US
cemiplimab (monotherapy), REGN2810, Libtayo, cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Regeneron Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
05/23
05/23
CA209-8TX, NCT02960230: H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

Completed
1/2
50
Europe, US
K27M peptide, Nivolumab
Sabine Mueller, MD, PhD, The V Foundation for Cancer Research, Pacific Pediatric Neuro-Oncology Consortium, Bristol-Myers Squibb
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
12/23
12/23
BLU-285-3101, NCT04773782 / 2020-005234-15: A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Active, not recruiting
1/2
37
Europe, Canada, US, RoW
avapritinib, BLU-285
Blueprint Medicines Corporation
Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor
02/25
12/25
NCT01748149: Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Active, not recruiting
1
40
Canada, US
Vemurafenib, RO5185426, PLX4032
University of California, San Francisco, Genentech, Inc.
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
12/18
12/25
NCT01922076: Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Completed
1
46
Canada, US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
12/20
09/22
PNOC016, NCT03893487: Fimepinostat in Treating Brain Tumors in Children and Young Adults

Active, not recruiting
1
30
Europe, US
Fimepinostat, CUDC-907, Therapeutic Conventional Surgery
Sabine Mueller, MD, PhD, Pediatric Neuro-Oncology Consortium, Cannonball Kids' Cancer Foundation, Curis, Inc.
Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
10/22
08/27
NCT02962167: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Completed
1
34
US
Modified Measles Virus, MV-NIS, Modified Measles Virus Lumbar Puncture, MV-NIS LP
Sabine Mueller, MD, PhD, No More Kids With Cancer, The Matthew Larson Foundation for Pediatric Brain Tumors, Vyriad, Inc., Mayo Clinic
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
05/23
05/23
NCT04323046: Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Recruiting
1
20
Europe, US, RoW
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Sabine Mueller, MD, PhD, Pediatric Neuro-Oncology Consortium
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
03/26
03/29
PNOC017, NCT03749187: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Recruiting
1
78
US
PARP Inhibitor BGB-290, BGB-290, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
University of California, San Francisco, BeiGene USA, Inc.
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
06/26
07/29
PNOC025, NCT05169944: Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

Completed
1
13
US
Magrolimab, Anti-CD47 Monoclonal Antibody
University of California, San Francisco, Gilead Sciences
Brain Cancer, Malignant Brain Tumor, Recurrent Brain Tumor, Progressive Malignant Brain Tumor, Brain Tumor, Pediatric, Brain Tumor Adult
09/24
09/24
NCI-2021-00046, NCT04732065: ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Recruiting
1
208
Europe, US
ONC206, antagonist of dopamine receptor D2 (DRD2) /human mitochondrial caseinolytic protease P (ClpP)ClpP Agonist, DRD2 antagonist/ClpP agonist, Standard of Care Radiation Therapy, Radiation Therapy (RT), Cancer Radiotherapy, Optional Proton (1H) MR spectroscopy (MRS), MRS
Sabine Mueller, MD, PhD, Chimerix, Mithil Prasad Foundation, Storm the Heavens Fund, The ChadTough Defeat DIPG Foundation, National Cancer Institute (NCI), Dana-Farber Cancer Institute
Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm, Spinal Cord Glioma, World Health Organization (WHO) Grade III Glioma, CNS Tumor, Central Nervous System Tumor
05/27
07/27
PNOC028, NCT05887882: Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

Recruiting
1
24
US
Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells, UD TGFβi NK cells, UD TGFβi NK cell product, Implantation, Magnetic Resonance Imaging (MRI), MRI, Quality-of-Life Assessment, QOL Assessment
Sabine Mueller, MD, PhD, Rally Foundation, Washington University School of Medicine, Nationwide Children's Hospital, CureSearch, Tommy Strong Foundation
Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor, Pediatric Supratentorial Neoplasm
12/27
12/27
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27
PNOC018, NCT05478837: Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma

Recruiting
1
12
US
Cyclophosphamide, Cytoxan, Cycloblastin, Fludarabine, Fludara, Autologous Anti-H3.3K27M TCR-expressing T-cells, KIND T cells
University of California, San Francisco, The V Foundation, Parker Institute for Cancer Immunotherapy, Alliance for Cancer Gene Therapy
Diffuse Midline Glioma, H3 K27M-Mutant
08/29
08/29
PNOC008, NCT03739372: Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

Active, not recruiting
N/A
44
US
Specialized tumor board recommendation
University of California, San Francisco, Pacific Pediatric Neuro-Oncology Consortium, The V Foundation for Cancer Research
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
12/23
01/27
NCT05000905: Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training

Recruiting
N/A
70
US
Adaptive Attention Training, Questionnaires
University of California, San Francisco
Pediatric Cancer
05/25
05/25
PNOC027, NCT05057702: Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma

Recruiting
N/A
10
US
Specialized Tumor Board Treatment Plan, Individualized Treatment Plan, Specialized Treatment Plan
University of California, San Francisco, Washington University School of Medicine, St. Baldrick's Foundation, Ashion Analytics, University of Washington, Pediatric Neuro-Oncology Consortium
Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
12/25
01/28
NCT06000787: MCT for the Harvard/UCSF ROBIN Center

Recruiting
N/A
47
US
External beam radiotherapy, 131I-Metaiodobenzylguanidine (MIBG)
Brigham and Women's Hospital, Dana-Farber Cancer Institute, National Cancer Institute (NCI), University of California, San Francisco
Glioma, Childhood Brainstem, Neuroblastoma
08/28
08/28
Mittendorfer, Bettina
NCT05145452: n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy

Suspended
N/A
60
US
Fish-oil derived n-3 polyunsaturated fatty acids
University of Missouri-Columbia
Diabetic Neuropathies
12/25
12/25
OSAGM, NCT03408613: Obstructive Sleep Apnea and Glucose Metabolism

Suspended
N/A
80
US
Positive Airway Pressure, Supplemental Oxygen, Sham
University of Missouri-Columbia
Sleep Apnea, Glucose Metabolism Disorders
02/25
02/26
VAL, NCT06286761: Routine Validation and Reproducibility Testing of Laboratory Measures and Research Techniques Used for Metabolism Research

Recruiting
N/A
100
US
endothelial cell collection, MRI, DEXA, MRS, blood testing, mixed meal, oral glucose tolerance testing
Bettina Mittendorfer
Obesity
03/28
03/28
ATM, NCT06335771: Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

Recruiting
N/A
60
US
Dietary consultation weight loss intervention
Bettina Mittendorfer, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Washington University School of Medicine
Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
03/28
03/28
ATM, NCT06571474: Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

Recruiting
N/A
60
US
Bettina Mittendorfer, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Washington University School of Medicine
Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
03/28
03/28
GHRB-A, NCT06571487: Growth Hormone Resistance of Beta-cells

Not yet recruiting
N/A
30
NA
University of Missouri-Columbia
Gestational Diabetes, Obesity, Healthy
09/28
09/30
GHRB-B, NCT06571500: Growth Hormone Resistance of Beta-cells in Women and People

Not yet recruiting
N/A
30
NA
University of Missouri-Columbia
Healthy, Obesity
09/28
09/30
NCT03994367: Animal and Plant Proteins and Glucose Metabolism

Recruiting
N/A
100
US
High animal protein isolate, High animal protein whole food, High plant protein isolate, High plant protein whole food
University of Missouri-Columbia
Metabolic Syndrome, Metabolic Syndrome, Protection Against, Glucose Metabolism Disorders
02/25
04/25
NCT05179954: Lipoprotein Kinetics in T1D

Recruiting
N/A
30
US
Metabolic testing
University of Missouri-Columbia, University of Washington
Type 1 Diabetes
12/25
12/27
NCT05235464: High Protein Diet and Atherosclerosis

Recruiting
N/A
24
US
Standard meal, High animal protein meal, High plant protein meal, High plant protein meal with additional leucine
University of Missouri-Columbia
Atherosclerosis
03/26
03/27
NCT02994459: Study of Fat Tissue's Ability to Take up Sugar in the Obese Population

Active, not recruiting
N/A
90
US
Weight Loss
University of Missouri-Columbia
Glucose Metabolism Disorders
01/27
01/27
 

Download Options